Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 2
1993 4
1994 6
1995 3
1996 4
1997 2
1998 7
1999 1
2000 3
2001 4
2002 6
2003 3
2004 5
2005 5
2006 5
2007 3
2008 1
2011 1
2012 1
2014 1
2015 1
2016 2
2017 5
2018 2
2019 2
2020 3
2021 2
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. Heinemann V, et al. Among authors: heintges t. Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. Lancet Oncol. 2014. PMID: 25088940 Clinical Trial.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T, Stintzing S. Heinemann V, et al. Among authors: heintges t. Br J Cancer. 2021 Feb;124(3):587-594. doi: 10.1038/s41416-020-01140-9. Epub 2020 Nov 6. Br J Cancer. 2021. PMID: 33154570 Free PMC article. Clinical Trial.
SEN virus infection.
Sagir A, Kirschberg O, Heintges T, Erhardt A, Häussinger D. Sagir A, et al. Among authors: heintges t. Rev Med Virol. 2004 May-Jun;14(3):141-8. doi: 10.1002/rmv.421. Rev Med Virol. 2004. PMID: 15124231 Review.
[HIV-HBV-coinfection--diagnosis and therapy].
Koch S, Göbels K, Oette M, Heintges T, Erhardt A, Häussinger D. Koch S, et al. Among authors: heintges t. Dtsch Med Wochenschr. 2006 Aug 25;131(34-35):1873-7. doi: 10.1055/s-2006-949173. Dtsch Med Wochenschr. 2006. PMID: 16915550 Review. German. No abstract available.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Giessen-Jung C, Uhlig J, Peuser B, Denzlinger C, Stahler A, Weiss L, Heinrich K, Held S, Jung A, Kirchner T, Heinemann V. Fischer LE, et al. Among authors: heintges t. Br J Cancer. 2022 Sep;127(5):836-843. doi: 10.1038/s41416-022-01854-y. Epub 2022 May 30. Br J Cancer. 2022. PMID: 35637412 Free PMC article. Clinical Trial.
Hepatitis C virus: epidemiology and transmission.
Heintges T, Wands JR. Heintges T, et al. Hepatology. 1997 Sep;26(3):521-6. doi: 10.1002/hep.510260338. Hepatology. 1997. PMID: 9303478 Review. No abstract available.
Effects of CCK on pancreatic function and morphology.
Niederau C, Lüthen R, Heintges T. Niederau C, et al. Among authors: heintges t. Ann N Y Acad Sci. 1994 Mar 23;713:180-98. doi: 10.1111/j.1749-6632.1994.tb44065.x. Ann N Y Acad Sci. 1994. PMID: 8185159 Review.
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Liu L, Erickson NT, Ricard I, von Weikersthal LF, Lerch MM, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Scheithauer W, Link H, Höffkes HG, Moehler M, Gesenhues AB, Theurich S, Michl M, Modest DP, Algül H, Stintzing S, Heinemann V, Holch JW. Liu L, et al. Among authors: heintges t. Int J Cancer. 2022 Jan 1;150(1):112-123. doi: 10.1002/ijc.33775. Epub 2021 Sep 6. Int J Cancer. 2022. PMID: 34431518 Free article. Clinical Trial.
84 results